FDA Grants AP Status for Zydus Healthcare's Metformin Hydrochloride Supplement
The FDA has granted approval status (AP) for Zydus Healthcare's supplemental application ANDA203686 for Metformin Hydrochloride.
Therapeutic Area
Therapeutic area intelligence for Oral Hypoglycemic Agent with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.